Article

Fat Cell Hormones May Cause Breast Cancer Cell Growth

Hormones in body fat provide bridge between breast cancer and obesity.

Hormones produced by fat cells can promote breast cancer growth in obese individuals, a study published in the Journal of Applied Physiology found.

Previously, researchers thought of adipose tissue as a storage form of energy. Today, the fat cells are understood to be active cells that produce more than 400 adipokines (hormones), which enter into the blood and travel throughout the body.

Using a rodent model, researchers wanted to determine if the hormones found in body fat can account for the association between breast cancer and obesity. Furthermore, they wanted to see if interventions that target obesity counteract any of the life-threatening effects of breast cancer.

“Our research has found that the characteristics of hormones produced by fat cells in obese people can promote breast cancer growth, whereas in lean people it prevents growth,” said lead researcher Michael Connor. “The characteristics of those hormones differ depending on whether the person is lean or obese and that determines whether the cancer grows or not.”

The findings suggest that adiponectin and leptin are possible reasons for poorer chemotherapy response, and a higher risk of death in obese individuals compared with others. Authors noted that exercise, which does not have any of the harmful side effects as many cancer drugs, could be a potentially beneficial therapy in some breast cancer patients.

“Our study shows that voluntary and rigorous exercise can counteract, and even completely prevent the effects on cancer growth that are caused by obesity,” Connor said. “We also show that even moderate exercise can lead to slowing of breast cancer growth and that the more exercise you do, the greater the benefit.”

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards